Icelandic pharmaceutical entrepreneur Robert Wessman is staging a comeback in the generic drugs business, taking a 30 percent stake and the role of executive chairman at privately held U.S. firm Alvogen Group.
The move comes a year after Wessman stepped down as chief executive officer (CEO) of Actavis, the firm he pieced together into one of the world's biggest copycat drugmakers through a string of more than two dozen acquisitions.
Wessman, once dubbed the "Viking boss" by the Economist, told Reuters he now aims to make Alvogen one of the world's ten biggest generic drug makers by revenues in five years.
More at Reuters
No comments:
Post a Comment